On September 19, 2019 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body’s immune system to fight cancer, reported that Potomac Urology Center, PC ("PUC") has joined its Cchek early cancer detection study (Press release, Anixa Biosciences, SEP 19, 2019, View Source [SID1234539639]). PUC will provide patient samples for Anixa’s ongoing prostate cancer study, including support of clinical validation of Anixa’s Cchek Prostate Cancer Confirmation test.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Nilay M. Gandhi, who will serve as the Principal Investigator at PUC for the study, stated, "We’re excited to take part in the development of Anixa’s Cchek prostate cancer detection test and we look forward to the impact this test may have on improving patient care."

"We are pleased to have PUC join us as a key collaborator in the development of Cchek, our artificial intelligence driven liquid biopsy for early cancer detection," stated Dr. Amit Kumar, CEO of Anixa. "Further, we look forward to PUC’s participation as we prepare for the commercial launch of our Cchek Prostate Cancer Confirmation test later this year."

PUC is an expert urology practice committed to providing the highest quality care to patients throughout the Northern Virginia area in the diagnosis and treatment of urology related conditions.